HIV Vaccines in Sub-Saharan Africa: Linking Correlates of Protection, Early Immune Pathways, and ART Gaps to Advance Prophylactic and Therapeutic Strategies: A Systematic Review
Background: Sub-Saharan Africa (SSA) remains the epicenter of the global HIV epidemic, accounting for nearly two-thirds of people living with HIV worldwide. While antiretroviral therapy (ART) has transformed HIV into a manageable chronic condition by substantially reducing morbidity, mortality, and transmission, major challenges persist, including latent viral reservoirs, chronic immune activation, incomplete immune restoration, treatment access gaps, and structural barriers. Consequently, effective prophylactic and therapeutic HIV vaccines remain essential components of long-term HIV prevention and remission strategies. Objective: This systematic review synthesizes the current landscape of HIV vaccine research in SSA, focusing on immune correlates of protection, early immunological events following primary HIV infection, persistent challenges associated with ART, and emerging prophylactic and therapeutic vaccine strategies. Methods: This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. A comprehensive search of electronic databases identified 300 records using predefined search terms related to HIV vaccines, immune correlates of protection, ART-associated immune dysfunction, and vaccine efficacy. After removal of duplicates (n = 35), 265 records underwent title and abstract screening, with 165 articles assessed for full-text eligibility. Following application of predefined inclusion and exclusion criteria, 125 studies were included in the final qualitative synthesis. Data were extracted and narratively synthesized across four thematic domains: (i) correlates of HIV protection, (ii) immune responses during primary HIV infection, (iii) ART-related immunological and virological limitations, and (iv) advances in prophylactic and therapeutic HIV vaccine development. A formal risk-of-bias assessment was not performed due to substantial heterogeneity in study designs, populations, methodologies, and outcome measures, which limited comparability across studies. Results: Evidence from SSA cohorts indicates that effective HIV control is associated with a multifaceted immune profile involving broadly neutralizing antibodies, Fc-mediated antibody functions, HIV-specific T-cell responses, favorable cytokine signatures, mucosal immunity, and host genetic factors. Following primary infection, rapid innate immune activation, type I interferon signaling, depletion of CCR5？ CD4+ T cells in gut-associated lymphoid tissue, microbial
References
[1]
WHO (2026) HIV and AIDS. https://www.who.int/news-room/fact-sheets/detail/hiv-aids
[2]
WHO (2026) HIV Data and Statistics. https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/strategic-information/hiv-data-and-statistics
[3]
https://www.afro.who.int/health-topics/hivaids
[4]
IHME (2024) Sub-Saharan Africa Leads Global HIV Decline: Progress Made but UNAIDS 2030 Goals Hang in Balance, New IHME Study Finds. https://www.healthdata.org/news-events/newsroom/news-releases/sub-saharan-africa-leads-global-hiv-decline-progress-made-unaids
[5]
Agrati, C., Bartolini, B., Bordoni, V., Locatelli, F., Capobianchi, M.R., Di Caro, A., et al. (2023) Emerging Viral Infections in Immunocompromised Patients: A Great Challenge to Better Define the Role of Immune Response. FrontiersinImmunology, 14, Article ID: 1147871. https://doi.org/10.3389/fimmu.2023.1147871
[6]
Lau, C.Y., Adan, M.A. and Maldarelli, F. (2021) Why the HIV Reservoir Never Runs Dry: Clonal Expansion and the Characteristics of HIV-Infected Cells Challenge Strategies to Cure and Control HIV Infection. Viruses, 13, Article 2512. https://doi.org/10.3390/v13122512
[7]
Parker, R.G., Easton, D. and Klein, C.H. (2000) Structural Barriers and Facilitators in HIV Prevention: A Review of International Research. AIDS, 14, S22-S32. https://doi.org/10.1097/00002030-200006001-00004
[8]
Wagner, A. and Weinberger, B. (2020) Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives. FrontiersinImmunology, 11, Article ID: 717. https://doi.org/10.3389/fimmu.2020.00717
[9]
Gartner, M.J., Roche, M., Churchill, M.J., Gorry, P.R. and Flynn, J.K. (2020) Understanding the Mechanisms Driving the Spread of Subtype C HIV-1. EBioMedicine, 53, Article 102682. https://doi.org/10.1016/j.ebiom.2020.102682
[10]
Yang, X., Su, B., Zhang, X., Liu, Y., Wu, H. and Zhang, T. (2020) Incomplete Immune Reconstitution in HIV/AIDS Patients on Antiretroviral Therapy: Challenges of Immunological Non-Responders. Journal of Leukocyte Biology, 107, 597-612. https://doi.org/10.1002/jlb.4mr1019-189r
[11]
Stangl, A.L., Earnshaw, V.A., Logie, C.H., van Brakel, W., C. Simbayi, L., Barré, I., et al. (2019) The Health Stigma and Discrimination Framework: A Global, Crosscutting Framework to Inform Research, Intervention Development, and Policy on Health-Related Stigmas. BMC Medicine, 17, Article No. 31. https://doi.org/10.1186/s12916-019-1271-3
[12]
Kawuma, R., Nakamanya, S., Tarimo, E., Chimukuche, R.S., Ambindwile, J., Pamba, D., et al. (2026) Understanding Trial Designs and Acceptability of Participation in an HIV Vaccine Trial with Concurrent Randomisation to Oral Pre-Exposure Prophylaxis in East and Southern Africa: A Longitudinal Qualitative Study. Trials, 27, Article No. 412. https://doi.org/10.1186/s13063-026-09774-5
[13]
Kansiime, S., Hansen, C.H., Ruzagira, E., McCormack, S., Hayes, R. and Dunn, D. (2025) Challenges in Estimating the Counterfactual Placebo HIV Incidence Rate from a Registration Cohort: The Prepvacc Trial. Clinical Trials, 22, 289-300. https://doi.org/10.1177/17407745241304721
[14]
Goswami, S., Veeramachaneni, S. and Masurkar, P.P. (2025) Lenacapavir for HIV Prep: Narrative Review of Clinical Trials and Implications for Patient Access. Current Treatment Options in Infectious Diseases, 17, Article No. 5. https://doi.org/10.1007/s40506-024-00281-2
[15]
Diazgranados, C.A., Onami, T. and Anklesaria, P. (2025) Accelerating Innovation: Advancing Opportunities in HIV Vaccine Development. Current HIV Research, 23, 442-455. https://doi.org/10.2174/011570162x364991250710044947
[16]
Lockhart, E., Turner, D., Guastaferro, K., Szalacha, L.A., Alzate, H.T., Marhefka, S., et al. (2024) Increasing Pre-Exposure Prophylaxis (PrEP) in Primary Care: A Study Protocol for a Multi-Level Intervention Using the Multiphase Optimization Strategy (MOST) Framework. Contemporary Clinical Trials, 143, Article 107599. https://doi.org/10.1016/j.cct.2024.107599
[17]
Tanaka, K., Blessing Chikowore, T.J., Deeks, S.G., Estes, J.D., Ho, Y.C., Jiang, S., et al. (2025) Meeting Summary for Keystone Symposia on HIV Cure: Antiretroviral Therapy (ART)-Free Control of HIV Infection in Durban, South Africa, 2025. Pathogens and Immunity, 10, Article No. 196. https://doi.org/10.20411/pai.v10i2.885
[18]
Fabiyi, K.O., Ebiala, F.I., Eze, V.I., Bejide, V.O., Ayeni, B.O. and Bakare, M.O. (2026) Mapping and Characterizing Persistent HIV Reservoirs in Early-Treated Individuals: Implications for Cure-Focused Interventions. Journal of Contemporary Studies in Epidemiology and Public Health, 7, ep26012. https://doi.org/10.29333/jconseph/18112
[19]
Nembot Fogang, B.A., Debrah, L.B., Owusu, M., Agyei, G., Meyer, J., Gmanyami, J.M., et al. (2025) Helminth Coinfections Modulate Disease Dynamics and Vaccination Success in the Era of Emerging Infectious Diseases. Vaccines, 13, Article 436. https://doi.org/10.3390/vaccines13050436
[20]
Mahomed, S. (2024) Broadly Neutralizing Antibodies for HIV Prevention: A Comprehensive Review and Future Perspectives. Clinical Microbiology Reviews, 37, e00152-22. https://doi.org/10.1128/cmr.00152-22
[21]
Su, B., Dispinseri, S., Iannone, V., Zhang, T., Wu, H., Carapito, R., et al. (2019) Update on Fc-Mediated Antibody Functions against HIV-1 beyond Neutralization. Frontiers in Immunology, 10, Article No. 2968. https://doi.org/10.3389/fimmu.2019.02968
[22]
Kankundiye, P., Kia, P., Kankaka, E., Nabatanzi, R., Mahmoudi, T. and Nakanjako, D. (2026) Persistent Immune Dysfunction during Suppressive Antiretroviral Therapy: Implications for Analytical Treatment Interruption Trials for Chronic HIV Infections in Sub-Saharan Africa. Frontiers in Immunology, 17, Article ID: 1754996. https://doi.org/10.3389/fimmu.2026.1754996
[23]
Zhang, C. and Vermund, S.H. (2022) Voluntary Medical Male Circumcision for HIV Prevention: A Global Overview. Current HIV/AIDS Reports, 19, 474-483. https://doi.org/10.1007/s11904-022-00632-y
[24]
George, G., Beckett, S., Reddy, T., Govender, K., Cawood, C., Khanyile, D., et al. (2022) Determining HIV Risk for Adolescent Girls and Young Women (AGYW) in Relationships with “Blessers” and Age-Disparate Partners: A Cross-Sectional Survey in Four Districts in South Africa. BMC Public Health, 22, Article No. 973. https://doi.org/10.1186/s12889-022-13394-4
[25]
Thalia, O.P. (2024) The Intersection of HIV and Social Determinants of Health: A Comprehensive Review. Newport International Journal of Research in Medical Sciences, 5, 53-58. https://doi.org/10.59298/nijrms/2024/5.3.5358
[26]
Menza, T.W., Hixson, L.K., Lipira, L. and Drach, L. (2021) Social Determinants of Health and Care Outcomes among People with HIV in the United States. Open Forum Infectious Diseases, 8, ofab330. https://doi.org/10.1093/ofid/ofab330
[27]
Karakoese, Z., Ingola, M., Sitek, B., Dittmer, U. and Sutter, K. (2024) IFNα Subtypes in HIV Infection and Immunity. Viruses, 16, Article 364. https://doi.org/10.3390/v16030364
[28]
Yin, X., Langer, S., Zhang, Z., Herbert, K.M., Yoh, S., K？nig, R., et al. (2020) Sensor Sensibility—HIV-1 and the Innate Immune Response. Cells, 9, Article 254. https://doi.org/10.3390/cells9010254
[29]
Rogers, A.P., Mileto, S.J. and Lyras, D. (2023) Impact of Enteric Bacterial Infections at and Beyond the Epithelial Barrier. Nature Reviews Microbiology, 21, 260-274. https://doi.org/10.1038/s41579-022-00794-x
[30]
Mu, W., Kedia, N. and Zhen, A. (2025) Finetuning Type I Interferon Signaling to Enhance T Cell Immunity in HIV Infection. Viruses, 17, Article 774. https://doi.org/10.3390/v17060774
[31]
Moura, S.S.D., Caetano, D.G., Guimar？es, M.L., da Silva, R.K.M., Cabral, N., da Costa Cruz Silva, S., et al. (2025) Acute HIV Infection and ART Response: Insights into T Cell Subsets, Activation, Exhaustion, and Blood and GALT HIV Reservoir. Viruses, 17, Article 1381. https://doi.org/10.3390/v17101381
[32]
Gabriel, E.M. (2024) Cellular and Molecular Biomarkers of Intestinal Pathology Promoting Cardiovascular Disease in People with HIV Receiving Antiretroviral Therapy. Doctoral Dissertation, Université de Montréal.
[33]
Lebu, S., Kibone, W., Muoghalu, C.C., Ochaya, S., Salzberg, A., Bongomin, F., et al. (2023) Soil-Transmitted Helminths: A Critical Review of the Impact of Co-Infections and Implications for Control and Elimination. PLOS Neglected Tropical Diseases, 17, e0011496. https://doi.org/10.1371/journal.pntd.0011496
[34]
Magura, J., Nhari, S.R. and Nzimakwe, T.I. (2025) Barriers to ART Adherence in Sub-Saharan Africa: A Scoping Review toward Achieving UNAIDS 95-95-95 Targets. Frontiers in Public Health, 13, Article ID: 1609743. https://doi.org/10.3389/fpubh.2025.1609743
[35]
Zuma, K., Simbayi, L., Zungu, N., Moyo, S., Marinda, E., Jooste, S., et al. (2022) The HIV Epidemic in South Africa: Key Findings from 2017 National Population-Based Survey. International Journal of Environmental Research and Public Health, 19, Article 8125. https://doi.org/10.3390/ijerph19138125
[36]
Li, K., Liu, B., Ma, R. and Zhang, Q. (2023) HIV Tissue Reservoirs: Current Advances in Research. AIDS Patient Care and STDs, 37, 284-296. https://doi.org/10.1089/apc.2023.0028
[37]
Kreider, E.F. and Bar, K.J. (2022) HIV-1 Reservoir Persistence and Decay: Implications for Cure Strategies. Current HIV/AIDS Reports, 19, 194-206. https://doi.org/10.1007/s11904-022-00604-2
[38]
Borrajo, A. (2025) Breaking Barriers to an HIV-1 Cure: Innovations in Gene Editing, Immune Modulation, and Reservoir Eradication. Life, 15, Article 276. https://doi.org/10.3390/life15020276
[39]
Nkolola, J.P. and Barouch, D.H. (2024) Prophylactic HIV-1 Vaccine Trials: Past, Present, and Future. The Lancet HIV, 11, e117-e124. https://doi.org/10.1016/s2352-3018(23)00264-3
[40]
Mathews, J., Van Itallie, E., Li, Y., Wiehe, K. and Schmidler, S.C. (2026) Computing the Inducibility of Broadly Neutralizing Antibodies under a Context-Dependent Model of Affinity Maturation: Applications to Sequential Vaccine Design. The Journal of Immunology, 215, vkaf234. https://doi.org/10.1093/jimmun/vkaf234
[41]
Ahmed, S. and Herschhorn, A. (2024) MRNA-Based HIV-1 Vaccines. Clinical Microbiology Reviews, 37, e00041-24. https://doi.org/10.1128/cmr.00041-24
[42]
Sofroniou, A. and Ridley, A. (2025) A Systematic Review of Clinical Trials Using mRNA Vaccines for Infectious Diseases Other than COVID-19. British Journal of Biomedical Science, 82, Article 14557. https://doi.org/10.3389/bjbs.2025.14557
[43]
Gómez, C.E., Perdiguero, B., Usero, L., Marcos-Villar, L., Miralles, L., Leal, L., et al. (2021) Enhancement of the HIV-1-Specific Immune Response Induced by an mRNA Vaccine through Boosting with a Poxvirus MVA Vector Expressing the Same Antigen. Vaccines, 9, Article 959. https://doi.org/10.3390/vaccines9090959
[44]
Gu, R., Si, D., Lei, D., Xie, X., Li, Y. and Wen, H. (2026) Accelerate the Highly Efficient Development of mRNA Vaccines Through Advanced Computational Methods. Medicine Communications, 7, e70612. https://doi.org/10.1002/mco2.70612
[45]
Li, R., Yi, W., Qian, X., Hu, S., Shen, H., Yan, D., et al. (2026) Nanobiotechnology for Dendritic Cell-Based Cancer Immunotherapy. Cell Biomaterials, Article 100485. https://doi.org/10.1016/j.celbio.2026.100485
[46]
Leal, L., Lucero, C., Gatell, J.M., Gallart, T., Plana, M. and García, F. (2017) New Challenges in Therapeutic Vaccines against HIV Infection. Expert Review of Vaccines, 16, 587-600. https://doi.org/10.1080/14760584.2017.1322513
[47]
Li, S., Moog, C., Zhang, T. and Su, B. (2022) HIV Reservoir: Antiviral Immune Responses and Immune Interventions for Curing HIV Infection. Chinese Medical Journal, 135, 2667-2676. https://doi.org/10.1097/cm9.0000000000002479
[48]
Amuche, N.J., Emmanuel, E.I. and Innocent, N.E. (2017) HIV/AIDS in Sub-Saharan Africa: Current Status, Challenges and Prospects. Asian Pacific Journal of Tropical Disease, 7, 239-256. https://doi.org/10.12980/apjtd.7.2017d6-366
[49]
Beyrer, C., Tomaras, G.D., Gelderblom, H.C., Gray, G.E., Janes, H.E., Bekker, L., et al. (2024) Is HIV Epidemic Control by 2030 Realistic? The Lancet HIV, 11, e489-e494. https://doi.org/10.1016/s2352-3018(24)00098-5
[50]
Scott, G.Y. and Worku, D. (2024) HIV Vaccination: Navigating the Path to a Transformative Breakthrough—A Review of Current Evidence. Health Science Reports, 7, e70089. https://doi.org/10.1002/hsr2.70089
[51]
Hannah, S., Chinyenze, K., Shattock, R., Yola, N. and Warren, M. (2022) HIV Vaccines in 2022: Where to from Here? Journal of the International AIDS Society, 25, e25923. https://doi.org/10.1002/jia2.25923
[52]
Mgodi, N.M., Takuva, S., Edupuganti, S., Karuna, S., Andrew, P., Lazarus, E., et al. (2021) A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings. JAIDS Journal of Acquired Immune Deficiency Syndromes, 87, 680-687. https://doi.org/10.1097/qai.0000000000002649
[53]
Ghys, P.D., Voetsch, A.C., Justman, J.E., Patel, H., Devos, J.R., Brown, K., et al. (2022) HIV-1 Variants in Population-Based National Surveys in Sub-Saharan Africa, 2015-2022. Acquired Immune Deficiency Syndrome, 40, 982-991.
[54]
Hamooya, B.M., Mutembo, S., Muyunda, B., Mweebo, K., Kancheya, N., Sikazwe, L., et al. (2023) HIV Test-and-Treat Policy Improves Clinical Outcomes in Zambian Adults from Southern Province: A Multicenter Retrospective Cohort Study. Frontiers in Public Health, 11, Article ID: 1244125. https://doi.org/10.3389/fpubh.2023.1244125
[55]
Tadenfok, C., Fokam, J., Semengue, E.N.J., Mossiang, L., Oyie, S., Noumo, P., et al. (2026) Efficacy of Dolutegravir-Based Therapy in Achieving Virological Suppression in PLHIV in Low-and Middle-Income Countries: Real-World Evidence from a Large Clinical Cohort in Cameroon. BMC Infectious Diseases, 26, Article No. 765. https://doi.org/10.1186/s12879-026-13013-2
[56]
Green, D., Tordoff, D.M., Kharono, B., Akullian, A., Bershteyn, A., Morrison, M., et al. (2020) Evidence of Sociodemographic Heterogeneity across the HIV Treatment Cascade and Progress towards 90‐90‐90 in Sub‐Saharan Africa—A Systematic Review and Meta‐Analysis. Journal of the International AIDS Society, 23, e25470. https://doi.org/10.1002/jia2.25470
[57]
Bansi-Matharu, L., Moolla, H., Citron, D.T., Stover, J., Pickles, M., Martin-Hughes, R., et al. (2025) Identifying Gaps in the HIV Treatment Cascade in Africa: A Model Comparison Study. The Lancet Global Health, 13, e1006-e1019. https://doi.org/10.1016/s2214-109x(25)00121-4
[58]
Chowdhury, M.T., Bershteyn, A., Milali, M., Citron, D.T., Nyimbili, S., Musuka, G., et al. (2025) Assessing Regional Variations and Sociodemographic Barriers in the Progress toward UNAIDS 95-95-95 Targets in Zimbabwe. Communications Medicine, 5, Article No. 106. https://doi.org/10.1038/s43856-025-00824-8
[59]
Makofane, K., van der Elst, E.M., Walimbwa, J., Nemande, S. and Baral, S.D. (2020) From General to Specific: Moving Past the General Population in the HIV Response across Sub‐Saharan Africa. Journal of the International AIDS Society, 23, e25605. https://doi.org/10.1002/jia2.25605
[60]
Terefe, B., Jembere, M.M., Asgedom, D.K. and Lakew, A.M. (2024) Knowledge and Attitude to HIV Pre Exposure Prophylaxis among Women in Five Sub-Saharan African Countries: A Multilevel Model Analysis of Population-Based Survey 2021-2022. BMC Public Health, 24, Article No. 1253. https://doi.org/10.1186/s12889-024-18717-1
[61]
Sisamu, M.F. (2024) Perceptions of Adolescent Girls and Young Women Regarding HIV Pre-Exposure Prophylaxis Usage at Public Health Facilities in Katima Mulilo, Zambezi Region, Namibia. Doctoral Dissertation, University of Namibia.
[62]
Tetteh, J.K., Frimpong, J.B., Budu, E., Adu, C., Mohammed, A., Ahinkorah, B.O., et al. (2021) Comprehensive HIV/AIDS Knowledge and HIV Testing among Men in Sub-Saharan Africa: A Multilevel Modelling. Journal of Biosocial Science, 54, 975-990. https://doi.org/10.1017/s0021932021000560
[63]
Nakanjako, D., Kankaka, E.N., Lungu, C., Galiwango, R.M., Reynolds, S.J., Mahmoudi, T., et al. (2025) HIV Cure Research Contributions from Africa in the Last Three Decades. Frontiers in Immunology, 16, Article ID: 1576667. https://doi.org/10.3389/fimmu.2025.1576667
[64]
Nachega, J.B., Kapata, N., Sam-Agudu, N.A., Decloedt, E.H., Katoto, P.D.M.C., Nagu, T., et al. (2021) Minimizing the Impact of the Triple Burden of COVID-19, Tuberculosis and HIV on Health Services in Sub-Saharan Africa. International Journal of Infectious Diseases, 113, S16-S21. https://doi.org/10.1016/j.ijid.2021.03.038
[65]
Tapera, T., Odimegwu, C., Petlele, R., Sello, M.V., Dzomba, A., Aladejebi, O., et al. (2023) Intersecting Epidemics: COVID-19 and HIV in Sub-Saharan Africa. A Systematic Review (2020-2022). Journal of Public Health in Africa, 14, Article No. 2658. https://doi.org/10.4081/jphia.2023.2658
[66]
Bain, L.E. and Dobermann, D. (2022) Malaria, HIV and TB in the Democratic Republic of the Congo: Epidemiology, Disease Control Challenges and Interventions. https://doi.org/10.19088/K4D.2022.034
[67]
Chanda-Kapata, P., Ntoumi, F., Kapata, N., Lungu, P., Mucheleng’anga, L.A., Chakaya, J., et al. (2022) Tuberculosis, HIV/AIDS and Malaria Health Services in Sub-Saharan Africa—A Situation Analysis of the Disruptions and Impact of the COVID-19 Pandemic. International Journal of Infectious Diseases, 124, S41-S46. https://doi.org/10.1016/j.ijid.2022.03.033
[68]
Jefferis, K., Avalos, A., Phillips, H., Mmelesi, M., Ramaabya, D., Nkomo, B., et al. (2021) Five Years after Treat All Implementation: Botswana’s HIV Response and Future Directions in the Era of COVID-19. Southern African Journal of HIV Medicine, 22, 1-11. https://doi.org/10.4102/sajhivmed.v22i1.1275
[69]
Moodie, Z., Dintwe, O., Sawant, S., Grove, D., Huang, Y., Janes, H., et al. (2022) Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. The Journal of Infectious Diseases, 226, 246-257. https://doi.org/10.1093/infdis/jiac260
[70]
Gray, G., Williamson, C., Bekker, L., Daniels, B., Smidt, W., Garrett, N., et al. (2025) Africa Is an Essential Partner in the Research and Development of an HIV Vaccine. Current HIV Research, 23, 482-493. https://doi.org/10.2174/011570162x361496250627004203
[71]
Chanda, C., Kibengo, F., Mutua, M., Ogada, F., Muturi-Kioi, V., Akis Yildirim, B.M., et al. (2025) Safety and Broad Immunogenicity of Hivconsvx Conserved Mosaic Candidate T-Cell Vaccines Vectored by Chadox1 and MVA in HIV-CORE 006: A Double-Blind, Randomised, Placebo-Controlled Phase 1 Trial in Healthy Adults Living without HIV-1 in Eastern and Southern Africa. The Lancet Microbe, 6, Article 101041. https://doi.org/10.1016/j.lanmic.2024.101041
[72]
Bright, B., Babalola, C.P., Sam-Agudu, N.A., Onyeaghala, A.A., Olatunji, A., Aduh, U., et al. (2021) COVID-19 Preparedness: Capacity to Manufacture Vaccines, Therapeutics and Diagnostics in Sub-Saharan Africa. Globalization and Health, 17, Article No. 24. https://doi.org/10.1186/s12992-021-00668-6
[73]
Gray, G.E., Mngadi, K., Lavreys, L., Nijs, S., Gilbert, P.B., Hural, J., et al. (2024) Mosaic HIV-1 Vaccine Regimen in Southern African Women (Imbokodo/HVTN 705/HPX2008): A Randomised, Double-Blind, Placebo-Controlled, Phase 2b Trial. The Lancet Infectious Diseases, 24, 1201-1212. https://doi.org/10.1016/s1473-3099(24)00358-x
[74]
Knisely, J.M. and Erbelding, E. (2025) Vaccines for Global Health: Progress and Challenges. The Journal of Infectious Diseases, 232, 25-27. https://doi.org/10.1093/infdis/jiae511
[75]
Shapiro, R.L., Ajibola, G., Maswabi, K., Hughes, M., Nelson, B.S., Niesar, A., et al. (2023) Broadly Neutralizing Antibody Treatment Maintained HIV Suppression in Children with Favorable Reservoir Characteristics in Botswana. Science Translational Medicine, 15, eadh0004. https://doi.org/10.1126/scitranslmed.adh0004
[76]
Bassoum, O., Kimura, M., Tal Dia, A., Lemoine, M. and Shimakawa, Y. (2020) Coverage and Timeliness of Birth Dose Vaccination in Sub-Saharan Africa: A Systematic Review and Meta-Analysis. Vaccines, 8, Article 301. https://doi.org/10.3390/vaccines8020301
[77]
Ngcobo, N., Jaca, A., Iwu-Jaja, C.J. and Mavundza, E. (2021) Reflection: Burden of Cervical Cancer in Sub-Saharan Africa and Progress with HPV Vaccination. Current Opinion in Immunology, 71, 21-26. https://doi.org/10.1016/j.coi.2021.03.006
[78]
Adeyanju, G.C., Essoh, T., Sidibe, A.R., Kyesi, F. and Aina, M. (2024) Human Papillomavirus Vaccination Acceleration and Introduction in Sub-Saharan Africa: A Multi-Country Cohort Analysis. Vaccines, 12, Article 489. https://doi.org/10.3390/vaccines12050489
[79]
Alum, E.U., Ainebyoona, C., Egwu, C.O., Onohuean, H., Ugwu, O.P.C., Uti, D.E., et al. (2025) Mitigation of Malaria in Sub-Saharan Africa through Vaccination: A Budding Road Map for Global Malaria Eradication. Ethiopian Journal of Health Sciences, 35, 205-217. https://doi.org/10.4314/ejhs.v35i3.9
[80]
Makuza, J.D., Tuyishime, A., Janjua, N. and Gupta, N. (2022) HBV Elimination in Sub-Saharan Africa: Rwanda’s Approach to Health System Integration. The Lancet Gastroenterology & Hepatology, 7, 511-512. https://doi.org/10.1016/s2468-1253(22)00134-0
[81]
Orozco, F., Benham, C., Xiang, C., Vemulapalli, A., Hancock, C., Rahim, F.O., et al. (2026) Leveraging HIV/AIDS Infrastructure for Sustainable Healthcare Services in Sub-Saharan Africa. AIDS, 40, 1034-1038. https://doi.org/10.1097/qad.0000000000004486
[82]
Dzinamarira, T., Rwibasira, G., Mwila, L., Moyo, E., Mangoya, D., Moyo, P., et al. (2025) Advancing Sustainable HIV Services through Integration in Primary Healthcare in Sub-Saharan Africa: A Perspective on Practical Recommendations. Healthcare, 13, Article 192. https://doi.org/10.3390/healthcare13020192
[83]
Hontelez, J.A.C., Goymann, H., Berhane, Y., Bhattacharjee, P., Bor, J., Chabata, S.T., et al. (2025) The Impact of the PEPFAR Funding Freeze on HIV Deaths and Infections: A Mathematical Modelling Study of Seven Countries in Sub-Saharan Africa. eClinicalMedicine, 83, Article 103233. https://doi.org/10.1016/j.eclinm.2025.103233
[84]
Kulohoma, B.W. and Wesonga, C.A. (2025) HIV Response Financing Challenges in Sub-Saharan Africa: Barriers to Achieving the 95-95-95 UNAIDS Targets. Frontiers in Public Health, 13, Article ID: 1658229. https://doi.org/10.3389/fpubh.2025.1658229
[85]
Mennechet, F.J.D. and Dzomo, G.R.T. (2020) Coping with COVID-19 in Sub-Saharan Africa: What Might the Future Hold? Virologica Sinica, 35, 875-884. https://doi.org/10.1007/s12250-020-00279-2
[86]
Kisa, A. and Kisa, S. (2025) Health Conspiracy Theories: A Scoping Review of Drivers, Impacts, and Countermeasures. International Journal for Equity in Health, 24, 93. https://doi.org/10.1186/s12939-025-02451-0
[87]
Cowan, F.M., Shahmanesh, M., Revill, P.A., Busza, J., Sibanda, E.L., Chabata, S.T., et al. (2025) Preventing HIV in Women in Africa. Nature Medicine, 31, 762-771. https://doi.org/10.1038/s41591-025-03535-8
[88]
Maughan-Brown, B., Egbe, T.I., Bokolo, S., Rabin, M., Chetty-Makkan, C., Kornides, M., et al. (2026) Understanding HIV Vaccine Misinformation and Vaccine Intentions among Young Women in South Africa: Insights from an Online Survey. AIDS and Behavior, 30, 2202-2210. https://doi.org/10.1007/s10461-026-05045-1
